MCM
AIMT

Manchester Capital Management’s Aimmune Therapeutics AIMT Stock Holding History

Manchester Capital Management’s Portfolio AIMT Stock Details AIMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-1,199
Closed -$27K – 673
2019
Q1 		$27K Buy
+1,199
New +$28.2K ﹤0.01% 488

Other funds holding AIMT

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
FCMI
Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
AC
Aisling Capital New York $45.3M AUM 15.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Manchester Capital Management's AIMT Position: Q2 2019 in Review

Manchester Capital Management sold out of Aimmune Therapeutics (AIMT) in Q2 2019, closing a stake of 1,199 shares — an estimated $27K sold.

Manchester Capital Management first reported a position in AIMT in Q1 2019 and held it in 1 quarter. The position peaked at $27K in Q1 2019. 125 funds tracked by Wall St. Rank hold AIMT as of Q2 2019.

  • Manchester Capital Management reported no remaining Aimmune Therapeutics position as of Q2 2019 after selling out during the quarter.
  • Manchester Capital Management sold 1,199 Aimmune Therapeutics shares in Q2 2019, an estimated $27K.
  • Manchester Capital Management first reported a position in Aimmune Therapeutics in Q1 2019 and held it in 1 quarter.
  • Manchester Capital Management's Aimmune Therapeutics position peaked at $27K in Q1 2019.
  • 125 funds tracked by Wall St. Rank held Aimmune Therapeutics as of Q2 2019.

Based on Manchester Capital Management's 13F filing for Q2 2019, filed 5 Aug 2019.